Given the high frequency of alterations in the PI3K/AKT signaling pathway in cancer and the well-established role of AKT signaling in mediating tumor survival and progression, inhibition of this pathway represents an attractive therapeutic approach in oncology1. The gene discussed is PIK3CA; the disease is cancer.